More importantly, increasing evidence has documented that HDAC inhibitors improve radiosensibility in malignancies, including lung cancer, colon cancer, glioma and squamous cell carcinoma [28–31], suggesting the implication of HDACs in tumor radiation resistance. This evidence concerns the gene HDAC9 and squamous cell carcinoma.